GH Research (NASDAQ:GHRS) Price Target Raised to $40.00 at Cantor Fitzgerald

GH Research (NASDAQ:GHRS) had its price target upped by Cantor Fitzgerald from $35.00 to $40.00 in a research report sent to investors on Friday morning, Marketbeat reports. The firm currently has an overweight rating on the stock.

A number of other equities research analysts have also issued reports on the stock. Zacks Research lowered shares of GH Research from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 15th. HC Wainwright decreased their price target on GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Citizens Jmp lowered their price objective on GH Research from $42.00 to $39.00 and set a “market outperform” rating for the company in a report on Friday, May 15th. Wells Fargo & Company initiated coverage on GH Research in a research note on Monday, July 27th. They set an “overweight” rating and a $44.00 price objective on the stock. Finally, Needham & Company LLC increased their target price on GH Research from $32.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday. Ten investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.78.

GH Research Trading Down 1.2%

Shares of NASDAQ:GHRS opened at $30.27 on Friday. The company has a fifty day simple moving average of $25.70 and a 200 day simple moving average of $20.16. The firm has a market cap of $2.08 billion, a PE ratio of -30.27 and a beta of 1.29. GH Research has a 12-month low of $11.32 and a 12-month high of $31.44.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.06. As a group, equities research analysts forecast that GH Research will post -1.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of GHRS. Troluce Capital Advisors LLC boosted its holdings in shares of GH Research by 165.4% in the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock valued at $13,926,000 after buying an additional 617,260 shares during the period. Avoro Capital Advisors LLC acquired a new stake in GH Research during the fourth quarter worth about $22,860,000. CenterBook Partners LP lifted its holdings in GH Research by 70.6% in the fourth quarter. CenterBook Partners LP now owns 283,441 shares of the company’s stock worth $3,600,000 after acquiring an additional 117,288 shares during the last quarter. BIT Capital GmbH bought a new position in GH Research in the fourth quarter worth about $635,000. Finally, Renaissance Technologies LLC bought a new position in GH Research in the first quarter worth about $290,000. 56.90% of the stock is currently owned by institutional investors.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.